IQVIA HOLDINGS INC. (IQV) IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
Sector: Services-Commercial Physical & Biological Research
Industry: Medical - Diagnostics & Research
IQVIA Holdings Inc. NYSE:IQV Healthcare · Medical - Diagnostics & Research
Mkt Cap $44.06B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ● Major ⚠ 3
IQVIA Reports Third-Quarter 2026 Results
IQVIA posted record Q3 2026 results with revenue of $4,428 million, up 8.0% YoY, and adjusted diluted EPS of $3.34, up 11.3% -- all headline metrics exceeded the high end of management's expectations.
Net new bookings rose 15% to $3.2 billion (1.2x book-to-bill), the strongest clinical quarterly bookings since 2022, and R&DS backlog stands at $32.6 billion with ~$9.4 billion expected to convert to revenue over the next twelve months.
The company raised full-year 2026 guidance for revenue ($17.35-$17.50B), adjusted EBITDA ($4.025-$4.055B) and adjusted EPS ($12.90-$13.00), with 250bps of revenue contribution from acquisitions.
Note: the company booked a ~$2.1 billion backward adjustment to backlog from a review of inactive trials, which does not affect guidance, book-to-bill or historical results. Net leverage is 3.45x LTM adjusted EBITDA.
• 5d ago AI analysis › Press Release ⚠ 2
The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape
FN Media published a paid promotional roundup on the AI healthcare theme, listing IQVIA among active companies and recapping industry news from Rocket Doctor AI, WELL Health, Tempus, and HEALWELL AI.
The only IQVIA-specific content is a recap of the previously announced expansion of its Veeva partnership, selecting Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise standards across IQVIA clinical development studies.
The release contains no new IQVIA financial figures, guidance, or corporate events; the publisher discloses it was compensated by Rocket Doctor AI and is unaffiliated with the companies named.
• 17d ago AI analysis › Press Release
IQVIA Selects Veeva Clinical Operations Applications
IQVIA selected Veeva CTMS, eTMF, Study Startup, and Site Connect as enterprise-standard clinical operations applications across its clinical development studies.
The move expands the EDC partnership the two companies announced previously and makes the full Veeva technology stack available to sponsors through IQVIA.
IQVIA emphasizes customers retain flexibility to choose IQVIA's own EDC, RTSM, and eCOA technologies; no financial terms were disclosed.
• 19d ago AI analysis › Press Release
IQVIA Launches IQVIA Explorer to Help Life Sciences Companies Make Better Commercial Decisions
IQVIA launched IQVIA Explorer at its TechIQ 2026 event, an always-on commercial intelligence platform for life sciences customers.
The product compresses analytics workflows that previously took weeks into minutes, such as brand share analysis in under 15 minutes and resource-planning analysis in under an hour.
The launch strengthens IQVIA's AI-enabled commercial offering but includes no financial terms or customer commitments, making it a modest positive rather than a market-moving event.
• 25d ago AI analysis › Press Release
IQVIA Launches IQVIA Life Science Models to Help Life Sciences Companies Predict Clinical Trial Outcomes
IQVIA introduced IQVIA Life Science Models at its TechIQ 2026 event, a suite of purpose-built AI models to help life sciences companies predict clinical trial outcomes.
Built on NVIDIA Nemotron and running on AWS infrastructure, the models support study simulation, protocol optimization, digital twins and synthetic controls. In initial evaluation across 50 trials and 270 endpoints, 85% of predictions were on target or clinically close.
The launch extends IQVIA's Predictive Clinical Development approach and could deepen its clinical research franchise, though no revenue figures or commercial terms were disclosed.
• 25d ago AI analysis › Press Release
IQVIA to Announce Third-Quarter 2026 Results on October 27, 2026
IQVIA will announce its third-quarter 2026 financial results before market open on Tuesday, October 27, 2026, with a conference call and webcast at 9:00 a.m. ET.
The release and financial materials will be posted on the IQVIA Investor Relations website, and a webcast replay will be available approximately two hours after the live event.
This is a scheduling notice only and contains no financial results or guidance.
• 1mo ago AI analysis › Press Release ⚠ 1
IQVIA Announces Pricing of Senior Notes
IQVIA Holdings priced a $2 billion offering of senior notes due 2034 through its wholly owned subsidiary IQVIA Inc., bearing interest at 6.375% per annum with semi-annual payments beginning March 15, 2027.
Proceeds will be used to redeem in full the Issuer's 5.000% notes due 2026, repay a portion of the revolving credit facility, and pay offering fees and expenses.
The notes are being sold as a private Rule 144A / Regulation S placement without Securities Act registration, with issuance expected on or about September 23, 2026.
• 1mo ago AI analysis › Press Release
IQVIA Announces Offering of Senior Notes
IQVIA's wholly owned subsidiary IQVIA Inc. intends to raise $2,000,000,000 through an offering of senior notes due 2034.
Proceeds will redeem in full the issuer's Senior 5.000% Notes due 2026 and repay a portion of the outstanding revolving credit facility, with the remainder covering offering fees and expenses.
The notes are being offered privately to qualified institutional buyers under Rule 144A and to non-U.S. investors under Regulation S, with consummation subject to market and customary conditions — a routine maturity-extension refinancing rather than new capital for growth.
• 1mo ago AI analysis › Press Release ⚠ 2
IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster
IQVIA launched Predictive Clinical Development, an AI-powered approach designed to help life sciences sponsors cut avoidable delays and bring new therapies to patients up to two years faster.
The company cites measurable efficiency claims across the development lifecycle: 33% faster study startup, 1.7 times more patients recruited with 42% higher enrollment rates, 50% faster data cleaning, and 45%+ less time between trial phases.
The platform pairs IQVIA's proprietary data and Healthcare-grade AI with technologies from Anthropic, Amazon Web Services, Databricks, Microsoft, NVIDIA, Palantir and Snowflake to drive agentic workflows.
The release contains no financial figures or contract wins; it is a competitive positioning announcement for IQVIA's R&D solutions segment, with all efficiency metrics self-reported rather than independently verified.
• 1mo ago AI analysis › Press Release
IQVIA Wins Multiple Industry Awards for AI and Technology Innovation Across Life Sciences and Healthcare
IQVIA announced it received recognition from multiple independent industry awards programs for its use of AI to support life sciences and healthcare organizations.
Notable honors include the AI Breakthrough Award for predictive modeling and the MedTech Breakthrough Award for the Privacy Analytics Platform, which currently integrates data for 55 million patients via the NHS.
Additionally, the IQVIA Literature AI Platform and the IRT Supply Automation Value Engine (SAVE) were recognized with Stevie Awards for their efficiency in scientific literature review and clinical trial supply management.
• 2mo ago AI analysis › Press Release
IQVIA's AI-Enabled Clinical Decision Support Tool Wins 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year
IQVIA's AI-enabled Clinical Decision Support Tool won the 2026 AI Breakthrough Award for Predictive Modeling Solution of the Year.
The tool demonstrated strong efficacy in practice, cutting screening workload by 99.5% and delivering a ~127x increase in diagnostic yield for identifying Type 1 diabetes.
Developed in partnership with Breakthrough T1D, the solution aims to close gaps in diabetes care by accelerating the path to correct diagnosis.
• 2mo ago AI analysis › Press Release
IQVIA Ranked No. 1 Pharmaceutical Technology Provider by Everest Group
IQVIA was ranked the No. 1 Pharmaceutical Technology Provider in Everest Group’s 2026 report, achieving an overall score of 96.8 out of 100.
The company was the only provider evaluated to cover all six pharmaceutical value-chain areas, ranging from drug discovery to pharmacovigilance.
This ranking reinforces IQVIA's breadth of technology coverage and its ability to support highly regulated life sciences environments.
• 2mo ago AI analysis › Press Release
IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery
IQVIA announced a strategic collaboration with Medera Inc. to accelerate the development of cardiac gene therapies and human-based drug discovery platforms.
The partnership leverages IQVIA’s global clinical trial infrastructure and regulatory expertise to support Medera’s Sardocor gene therapy programs and Novoheart’s mini-Heart tissue platforms.
IQVIA will assist with patient recruitment, data quality, and regulatory filings, including applications for expedited FDA designations for Medera’s AAV-based therapies.
• 2mo ago AI analysis › Press Release ● Major
IQVIA Reports Second-Quarter 2026 Results
IQVIA reported Q2 revenue of $4.37 billion, up 8.7% year-over-year, with Adjusted EPS of $3.15 increasing 12.1%.
The R&D Solutions segment delivered record net new bookings of $3.15 billion, representing a 19% increase, while total Adjusted EBITDA grew 9.2% to $994 million.
Management raised full-year 2026 guidance for revenue, Adjusted EBITDA, and Adjusted EPS, citing a strengthening market environment and strong organic growth.
• 3mo ago AI analysis › Press Release
IQVIA's Dr. Cynthia Verst Testifies Before Congressional Subcommittee on More Efficient Path to Early Clinical Development in the United States
IQVIA executive Dr. Cynthia Verst testified before the U.S. House Subcommittee on Health regarding the modernization of early clinical development in the United States.
Verst recommended creating a more efficient path from discovery to first-in-human studies while maintaining the FDA’s safety standards and improving regulatory engagement.
The testimony highlighted the need to strengthen infrastructure and support emerging biopharmaceutical companies, which drive the majority of new Phase I trial starts.
• 3mo ago AI analysis › Press Release
IQVIA to Announce Second-Quarter 2026 Results on July 28, 2026
IQVIA Holdings announced it will release its second-quarter 2026 financial results before the market opens on Tuesday, July 28, 2026.
Management is scheduled to host a conference call and webcast at 9:00 a.m. Eastern Time on the same day to discuss the quarterly performance.
Interested parties must register in advance via the company's Investor Relations website to participate in the live event.
• 3mo ago AI analysis › Press Release
StackAdapt Teams Up with IQVIA Digital's MediaOS to Power Healthcare Advertising
businesswire.com • 4mo ago Press Release
Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain
IQVIA and Wiley released a joint cross-sector report titled 'Scientific Discovery & AI: The Science-to-Patient Journey.'
The report synthesizes insights from an invitation-only summit hosted in May 2026, featuring over 25 senior leaders from pharma, academia, and technology.
The release highlights structural gaps in AI adoption across the healthcare value chain but does not announce new commercial deals, revenue, or specific product launches for IQVIA.
• 4mo ago AI analysis › Press Release
IQVIA Announces Pricing of Senior Notes
IQVIA priced €950 million in senior notes due 2033 through its wholly owned subsidiary IQVIA Inc.
The notes carry a 4.625% annual interest rate, payable semi-annually, with settlement expected on June 11, 2026.
Proceeds will be used to refinance existing indebtedness and cover offering fees, representing a standard balance sheet maintenance activity rather than a strategic shift.
• 4mo ago AI analysis › Press Release
IQVIA Announces Offering of Senior Notes
IQVIA announced an offering of €950 million in senior notes due 2033 through its wholly owned subsidiary, IQVIA Inc.
The proceeds will be used to refinance existing indebtedness and pay associated fees and expenses.
The offering is subject to market conditions and customary closing requirements, with no specific pricing or interest rate disclosed in this announcement.
• 4mo ago AI analysis › Press Release
IQVIA CEO to Speak at Jefferies Global Healthcare Conference
IQVIA announced that CEO Ari Bousbib will speak at the Jefferies Global Healthcare Conference on June 3, 2026, at 9:20 a.m. ET.
A live audio webcast of the presentation will be available on the company's Investor Relations website, with a replay provided later that day.
The release includes standard corporate boilerplate describing IQVIA's clinical research services and AI capabilities, noting approximately 93,000 employees globally.
• 5mo ago AI analysis › Press Release ● Major
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
IQVIA's board approved a $2 billion increase in its share repurchase authorization, raising the total remaining authorization to $3.2 billion.
The repurchase program is discretionary and can be modified or discontinued at any time, with no specific obligations to repurchase a particular amount.
The move signals management's confidence in the company's stock and could potentially boost investor sentiment.
• 5mo ago AI analysis › Press Release
IQVIA CFO to Speak at Bank of America Health Care Conference 2026
IQVIA announced that CFO Mike Fedock will present at the Bank of America Health Care Conference in Las Vegas on May 13, 2026.
The presentation is scheduled to begin at 1:40 p.m. ET, with a live audio webcast accessible on the company's investor relations website.
A replay of the session will be made available later the same day for those unable to attend the live broadcast.
• 5mo ago AI analysis › Press Release ● Major
IQVIA Reports First-Quarter 2026 Results
IQVIA reported Q1 revenue of $4.15 billion, up 8.4% year-over-year, with GAAP EPS of $1.61 and Adjusted EPS of $2.90.
The company reaffirmed full-year revenue and Adjusted EBITDA guidance while raising its Adjusted EPS outlook to a range of $12.65 to $12.95.
Free cash flow increased 15% to $491 million, representing 100% of Adjusted Net Income, supported by a $552 million share repurchase during the quarter.
• 5mo ago AI analysis › 
